Adni vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Singapore YC healthcare worker super app with 150K+ verified nurses for peer advice, jobs, and credential management at $1.8M ARR Jul 2025; $1.38M Flare Capital seed with Penn Medicine/MedPro partnerships competing with Doximity for allied health professionals.
About
Adni is a Singapore-headquartered AI-powered super app for healthcare workers — backed by Y Combinator with $1.38 million raised including a $1.25 million seed round in May 2022 from YC, Flare Capital Partners, and Fresco Capital — providing 150,000+ verified nurses and allied healthcare professionals with a unified platform for anonymous peer advice sharing, job discovery, credential management (universal professional profile storing licenses, certifications, and continuing education records), equipment procurement, and community resources, generating $1.8 million in annual revenue as of July 2025 with approximately 32 employees across Asia and North America. Adni partners with leading healthcare organizations including Penn Medicine, MedPro, and PRN Healthcare to provide nurses and allied health workers with the professional tools that their clinical training institutions and hospital employers don't provide.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.